Physiomics signs further project agreement with CellCentric
Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens for the biopharma industry, is delighted to announce that it has been awarded a further contract by existing UK based biotech client, CellCentric. The value of the contract is not disclosed but is expected to complete in the first half of...
Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens for the biopharma industry, is pleased to announce that, following a successful collaboration this year its client Merck KGaA ("Merck") has today committed to an initial tranche of projects for 2020 with an aggregate value of £250,000. These projects are expected to be...
The Company held its Annual General Meeting at its offices in Oxford on 19 November 2019 and is pleased to announce that all resolutions put to shareholders were duly passed.
Dr Jim Millen, CEO
+44 (0)1865 784 980
Strand Hanson Ltd (NOMAD)
Richard Tulloch & James Dance
+44 (0)20 7409 3494
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0)20 3764 2341
Notes to Editor
Physiomics plc (AIM: PYC) is a provider of technology-based...
Written by David Orrell
In a 1904 paper on weather forecasting, the Norwegian physicist and meteorologist Vilhelm Bjerknes noted that the accuracy of a predictive model depends on two things: “1. A sufficiently accurate knowledge of the state of the atmosphere at the initial time. 2. A sufficiently accurate knowledge of the laws according to which one state of the atmosphere develops from another.” Or in...
Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens, is pleased to announce that it has today posted to shareholders its Annual Report and Accounts for the financial year ended 30 June 2019 together with its Notice of Annual General Meeting (“AGM”).
As previously announced on the 30 September 2019, the Company’s AGM will be held at 10.00...
Total income (revenue and grant income) increased 53% to £783,101 (2018: £512,899)
The operating loss decreased 23% to £201,219 (2018 £260,391)
The loss after taxation decreased 43% to £104,040 (2018: £183,341)
At 30 June 2019, the surplus of shareholders’ funds was £607,914 (30 June 2018: £690,026)
Cash and cash equivalents at 30 June 2019 of £405,366 (30 June 2018: £571,869)
Click here to read in...
The Company announces that it received notice today that the following Directors acquired the following number of ordinary shares in the Company at the following prices per share.
Click here to read in full...
Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to confirm that, based on its unaudited management accounts for the year ended 30 June 2019, the Company is trading in line with analyst expectations.
The Company expects to publish its final audited results for the year ending 30 June 2019 during the...